|
 |
Evolution of the Norton-Simon hypothesis
|
| |
CALGB 9741: Phase III study of dose-dense
and sequential adjuvant chemotherapy
|
| |
Improved survival without increased toxicity with
dose-dense chemotherapy |
| |
Importance of hematopoetic support during dose-dense
therapy |
| |
Clinical applicability of CALGB 9741 data |
| |
Dose and schedule of adjuvant paclitaxel |
| |
Trastuzumab as first-line therapy in metastatic
disease |
| |
Phase III trial of trastuzumab and paclitaxel
with or without carboplatin |
| |
Advantages of capecitabine in the management of
metastatic disease |
| |
Capecitabine plus docetaxel as combination therapy |
| |
Select publications regarding
dose-dense chemotherapy; Hematopoetic growth factors |
| |
|
Postmastectomy radiation therapy in women
with one to three positive nodes
|
| |
Nonprotocol use of AC-docetaxel |
| |
Ovarian suppression in ER-positive, premenopausal
women: Intergroup Trial 0101 |
| |
Trials combining LHRH agonists and aromatase inhibitors
in premenopausal women |
| |
Tamoxifen versus anastrozole in postmenopausal
women |
| |
Use of bisphosphonates in the adjuvant setting |
| |
Capecitabine in the metastatic setting |
| |
Combination versus sequential therapy in the metastatic
setting |
| |
Adjuvant capecitabine trial in elderly women |
| |
Select publications regarding
adjuvant endocrine therapy in premenopausal patients |
| |
San
Antonio Breast Cancer Symposium
Clinical Trials Exhibit.
|
|
|
|
